Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative disorder closely related to immunity. An important aspect of the pathogenesis of PD is the interaction between α-synuclein and a series of immune cells. Studies have shown that accumulation of α-synuclein can induce an autoimmune response that accelera...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ruichen Su, Tian Zhou
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
Accès en ligne:https://doaj.org/article/0010b87d05e84d249d15557ca42e2e65
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
id oai:doaj.org-article:0010b87d05e84d249d15557ca42e2e65
record_format dspace
spelling oai:doaj.org-article:0010b87d05e84d249d15557ca42e2e652021-11-05T08:36:16ZAlpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease1663-436510.3389/fnagi.2021.769506https://doaj.org/article/0010b87d05e84d249d15557ca42e2e652021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fnagi.2021.769506/fullhttps://doaj.org/toc/1663-4365Parkinson’s disease (PD) is a neurodegenerative disorder closely related to immunity. An important aspect of the pathogenesis of PD is the interaction between α-synuclein and a series of immune cells. Studies have shown that accumulation of α-synuclein can induce an autoimmune response that accelerates the progression of PD. This study discusses the mechanisms underlying the interaction between α-synuclein and the immune system. During the development of PD, abnormally accumulated α-synuclein becomes an autoimmune antigen that binds to Toll-like receptors (TLRs) that activate microglia, which differentiate into the microglia type 1 (M1) subtype. The microglia activate intracellular inflammatory pathways, induce the release of proinflammatory cytokines, and promote the differentiation of cluster of differentiation 4 + (CD4 +) T cells into proinflammatory T helper type 1 (Th1) and T helper type 17 (Th17) subtypes. Given the important role of α-synuclein in the immune system of the patients with PD, identifying potential targets of immunotherapy related to α-synuclein is critical for slowing disease progression. An enhanced understanding of immune-associated mechanisms in PD can guide the development of associated therapeutic strategies in the future.Ruichen SuTian ZhouFrontiers Media S.A.articleParkinson’s disease (PD)α-synucleinmicrogliaT cellstherapeuticsNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENFrontiers in Aging Neuroscience, Vol 13 (2021)
institution DOAJ
collection DOAJ
language EN
topic Parkinson’s disease (PD)
α-synuclein
microglia
T cells
therapeutics
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
spellingShingle Parkinson’s disease (PD)
α-synuclein
microglia
T cells
therapeutics
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Ruichen Su
Tian Zhou
Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
description Parkinson’s disease (PD) is a neurodegenerative disorder closely related to immunity. An important aspect of the pathogenesis of PD is the interaction between α-synuclein and a series of immune cells. Studies have shown that accumulation of α-synuclein can induce an autoimmune response that accelerates the progression of PD. This study discusses the mechanisms underlying the interaction between α-synuclein and the immune system. During the development of PD, abnormally accumulated α-synuclein becomes an autoimmune antigen that binds to Toll-like receptors (TLRs) that activate microglia, which differentiate into the microglia type 1 (M1) subtype. The microglia activate intracellular inflammatory pathways, induce the release of proinflammatory cytokines, and promote the differentiation of cluster of differentiation 4 + (CD4 +) T cells into proinflammatory T helper type 1 (Th1) and T helper type 17 (Th17) subtypes. Given the important role of α-synuclein in the immune system of the patients with PD, identifying potential targets of immunotherapy related to α-synuclein is critical for slowing disease progression. An enhanced understanding of immune-associated mechanisms in PD can guide the development of associated therapeutic strategies in the future.
format article
author Ruichen Su
Tian Zhou
author_facet Ruichen Su
Tian Zhou
author_sort Ruichen Su
title Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
title_short Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
title_full Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
title_fullStr Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
title_full_unstemmed Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
title_sort alpha-synuclein induced immune cells activation and associated therapy in parkinson’s disease
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/0010b87d05e84d249d15557ca42e2e65
work_keys_str_mv AT ruichensu alphasynucleininducedimmunecellsactivationandassociatedtherapyinparkinsonsdisease
AT tianzhou alphasynucleininducedimmunecellsactivationandassociatedtherapyinparkinsonsdisease
_version_ 1718444449036500992